UroGen Pharma Ltd.

NasdaqGM:URGN Stock Report

Market Cap: US$192.3m

UroGen Pharma Future Growth

Future criteria checks 5/6

UroGen Pharma is forecast to grow earnings and revenue by 66% and 38.7% per annum respectively while EPS is expected to grow by 66.6% per annum.

Key information

66.0%

Earnings growth rate

66.63%

EPS growth rate

Biotechs earnings growth23.7%
Revenue growth rate38.7%
Future return on equityn/a
Analyst coverage

Good

Last updated22 May 2025

Recent future growth updates

Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63

May 15
Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Mar 17
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Recent updates

UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either

May 21

Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop

May 17
Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop

Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63

May 15
Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63
author-image

UGN-102 Approval Will Broaden Bladder Cancer Treatment Options

Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power.

Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet

Feb 12
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet

UroGen: Upcoming PDUFA, Some Concerns Remain

Jan 31

Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?

Nov 18
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?

UroGen Pharma: There Is Some Potential Here

Aug 28

UroGen: Q3 NDA Opens Hefty Revenue Opportunity

Jun 17

UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Jun 14
UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Apr 09
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

UroGen: All Eyes On UGN-102

Mar 18

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Mar 17
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 18
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough

Earnings and Revenue Growth Forecasts

NasdaqGM:URGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20273548489416
12/31/2026218-3913-158
12/31/2025117-138-34-1378
3/31/202592-138-107-107N/A
12/31/202490-127-97-97N/A
9/30/202489-115-96-96N/A
6/30/202485-114-86-86N/A
3/31/202484-104-82-82N/A
12/31/202383-102-77-76N/A
9/30/202377-105-85-85N/A
6/30/202373-109-86-85N/A
3/31/202368-112-90-89N/A
12/31/202264-110-88-88N/A
9/30/202262-109-86-86N/A
6/30/202258-114-87-87N/A
3/31/202254-113-82-81N/A
12/31/202148-111-86-85N/A
9/30/202140-113-87-86N/A
6/30/202132-111-94-93N/A
3/31/202119-117-99-98N/A
12/31/202012-128-107-106N/A
9/30/20204-137-112-111N/A
6/30/20200-130-99-98N/A
3/31/20200-121-89-89N/A
12/31/20190-105-71-71N/A
9/30/20190-90-55-55N/A
6/30/20190-88-52-52N/A
3/31/20191-84-46-46N/A
12/31/20181-76N/A-37N/A
9/30/20181-62N/A-33N/A
6/30/20189-42N/A-21N/A
3/31/20189-30N/A-16N/A
12/31/20178-21N/A-10N/A
9/30/2017252N/A10N/A
6/30/201718-7N/A4N/A
3/31/201718-4N/A4N/A
12/31/201618-4N/A4N/A
9/30/2016N/A-24N/A-11N/A
3/31/2016N/A-16N/A-8N/A
12/31/2015N/A-14N/A-7N/A
9/30/2015N/A-7N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: URGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).

Earnings vs Market: URGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: URGN is expected to become profitable in the next 3 years.

Revenue vs Market: URGN's revenue (38.7% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: URGN's revenue (38.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if URGN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 22:33
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

UroGen Pharma Ltd. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Jonathan AschoffB. Riley Wealth
Jason KolbertD. Boral Capital LLC.